171 related articles for article (PubMed ID: 23973113)
1. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.
Randle RW; Northrup SA; Sirintrapun SJ; Lyles DS; Stewart JH
Surgery; 2013 Dec; 154(6):1323-29; discussion 1329-30. PubMed ID: 23973113
[TBL] [Abstract][Full Text] [Related]
2. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
[TBL] [Abstract][Full Text] [Related]
4. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus as a treatment for colorectal cancer.
Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS
Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
8. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
Wu Y; Lun X; Zhou H; Wang L; Sun B; Bell JC; Barrett JW; McFadden G; Biegel JA; Senger DL; Forsyth PA
Clin Cancer Res; 2008 Feb; 14(4):1218-27. PubMed ID: 18281557
[TBL] [Abstract][Full Text] [Related]
11. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
[TBL] [Abstract][Full Text] [Related]
12. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
13. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
[TBL] [Abstract][Full Text] [Related]
15. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
16. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
[TBL] [Abstract][Full Text] [Related]
17. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
18. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
19. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
Paglino JC; van den Pol AN
J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.
Kloker LD; Berchtold S; Smirnow I; Beil J; Krieg A; Sipos B; Lauer UM
BMC Cancer; 2020 Jul; 20(1):628. PubMed ID: 32631270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]